Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study
PLOS One · 2025
DOI: 10.1371/journal.pone.0327842 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Yuting Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Gonadotropin-Releasing Hormone, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2024 PSM Guangdong Pharmaceutical Science Research Fund, 2024 Guangdong Provincial universities characteristic innovation project.
Abstract (Originalsprache)
Background
Long-acting Gonadotropin-releasing hormone analogs(GnRHa), including leuprolide, goserelin, histrelin, buserelin, triptorelin, have been widely used for a variety of diseases including prostate cancer, breast cancer, endometriosis, uterine leiomyomas, and central precocious puberty (CPP). However, their real-world safety profile differences have not been adequately compared.
Objective
We aimed to investigate the adverse event (AE) profile differences of long-acting GnRHa reported by the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods
All indications were searched long-acting GnRHa, as primary suspect drugs, from FAERS data (January 2004 to September 2023). We performed disproportionality analyses by reporting odds ratios (ROR) and conducted univariate and multivariate logistical regression analyses to determine the odds ratio (OR) of serious AEs associated with long-acting GnRHa under different exposure factors.
Results
Reproductive system and breast disorders accounted for the greatest proportion of adverse events among the five long-acting GnRHa formulations analyzed. Both buserelin and histrelin showed distinct adverse effect profiles, with buserelin demonstrating a higher incidence of gastrointestinal disorders and histrelin showing a greater propensity for psychiatric disorders. Logistic regression analysis revealed these five medications carried an elevated risk of significant medical events, and this risk was notably lower in pediatric patients (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, Guangdong, China.
- School of Pharmaceutical sciences, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Pharmacy, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
- Sun Yat-Sen University Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China.
- Guangzhou Civil Aviation College, Guangzhou, Guangdong, China.
- Department of Pharmacy, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Yuting Chen, Huancun Feng
Förderung
- 2024 PSM Guangdong Pharmaceutical Science Research Fund
- 2024 Guangdong Provincial universities characteristic innovation project
Zitieren
APA
Chen, Y., Lu, W., Liao, R., Zhang, X., Chen, W., Wang, J., & Feng, H. (2025). Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study. PLOS One. https://doi.org/10.1371/journal.pone.0327842
Vancouver
Chen Y, Lu W, Liao R, Zhang X, Chen W, Wang J, et al. Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study. PLOS One. 2025. doi:10.1371/journal.pone.0327842
BibTeX
@article{Chen2025,
author = {Chen, Yuting and Lu, Weitao and Liao, Ruilian and Zhang, Ximin and Chen, Wang and Wang, Jing and Feng, Huancun},
title = {Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0327842}
}
EUVIMED